CAS 1306760-86-0
:R-Ozanimod
Description:
Ozanimod is a selective sphingosine 1-phosphate receptor modulator, primarily targeting S1P receptors 1 and 5. It is designed for oral administration and is primarily investigated for its therapeutic potential in autoimmune diseases, particularly multiple sclerosis and ulcerative colitis. The compound works by modulating lymphocyte trafficking, effectively reducing the number of circulating lymphocytes and thereby mitigating inflammatory responses. Chemically, ozanimod is characterized by its unique structure, which includes a substituted phenyl ring and a piperidine moiety, contributing to its receptor selectivity and pharmacological profile. The substance has undergone various clinical trials to assess its efficacy and safety, demonstrating a favorable pharmacokinetic profile with a relatively long half-life, allowing for once-daily dosing. As with many pharmacological agents, potential side effects may include infections, liver enzyme elevations, and cardiovascular effects, necessitating careful monitoring during treatment. Overall, ozanimod represents a significant advancement in the management of chronic inflammatory conditions.
Formula:C23H24N4O3
Synonyms:- Benzonitrile, 5-[3-[(1R)-2,3-dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)-
- R-Ozanimod
Sort by
The purity filter is not visible because current products do not have associated purity data for filtering.
Found 1 products.
